JP2022522547A5 - - Google Patents

Info

Publication number
JP2022522547A5
JP2022522547A5 JP2020541718A JP2020541718A JP2022522547A5 JP 2022522547 A5 JP2022522547 A5 JP 2022522547A5 JP 2020541718 A JP2020541718 A JP 2020541718A JP 2020541718 A JP2020541718 A JP 2020541718A JP 2022522547 A5 JP2022522547 A5 JP 2022522547A5
Authority
JP
Japan
Prior art keywords
conjugate according
antibody conjugate
cancer
alkyl
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020541718A
Other languages
English (en)
Japanese (ja)
Other versions
JP7664045B2 (ja
JP2022522547A (ja
Filing date
Publication date
Priority claimed from KR1020200027373A external-priority patent/KR102503143B1/ko
Application filed filed Critical
Priority claimed from PCT/KR2020/003100 external-priority patent/WO2020180121A1/ko
Publication of JP2022522547A publication Critical patent/JP2022522547A/ja
Publication of JP2022522547A5 publication Critical patent/JP2022522547A5/ja
Priority to JP2025009671A priority Critical patent/JP2025076435A/ja
Application granted granted Critical
Publication of JP7664045B2 publication Critical patent/JP7664045B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020541718A 2019-03-06 2020-03-05 ヒトdlk1に対する抗体を含む抗体薬物コンジュゲート及びその使用 Active JP7664045B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025009671A JP2025076435A (ja) 2019-03-06 2025-01-23 ヒトdlk1に対する抗体を含む抗体薬物コンジュゲート及びその使用

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20190025987 2019-03-06
KR10-2019-0025987 2019-03-06
KR1020200027373A KR102503143B1 (ko) 2019-03-06 2020-03-04 인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
KR10-2020-0027373 2020-03-04
PCT/KR2020/003100 WO2020180121A1 (ko) 2019-03-06 2020-03-05 인간 dlk1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025009671A Division JP2025076435A (ja) 2019-03-06 2025-01-23 ヒトdlk1に対する抗体を含む抗体薬物コンジュゲート及びその使用

Publications (3)

Publication Number Publication Date
JP2022522547A JP2022522547A (ja) 2022-04-20
JP2022522547A5 true JP2022522547A5 (cg-RX-API-DMAC7.html) 2023-03-13
JP7664045B2 JP7664045B2 (ja) 2025-04-17

Family

ID=72337989

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020541718A Active JP7664045B2 (ja) 2019-03-06 2020-03-05 ヒトdlk1に対する抗体を含む抗体薬物コンジュゲート及びその使用
JP2025009671A Pending JP2025076435A (ja) 2019-03-06 2025-01-23 ヒトdlk1に対する抗体を含む抗体薬物コンジュゲート及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025009671A Pending JP2025076435A (ja) 2019-03-06 2025-01-23 ヒトdlk1に対する抗体を含む抗体薬物コンジュゲート及びその使用

Country Status (6)

Country Link
US (1) US20220339291A1 (cg-RX-API-DMAC7.html)
EP (1) EP3936150A4 (cg-RX-API-DMAC7.html)
JP (2) JP7664045B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021017303A2 (cg-RX-API-DMAC7.html)
MX (1) MX2021010453A (cg-RX-API-DMAC7.html)
WO (1) WO2020180121A1 (cg-RX-API-DMAC7.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101628872B1 (ko) * 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
HUE067016T2 (hu) 2015-11-25 2024-09-28 Ligachem Biosciences Inc Önfeláldozó csoportokat tartalmazó konjugátumok és ezekkel kapcsolos eljárások
CN107847605B (zh) 2015-11-25 2021-12-24 乐高化学生物科学股份有限公司 包含分支接头的抗体-药物缀合物及其相关方法
JP7120765B2 (ja) 2015-11-25 2022-08-17 レゴケム バイオサイエンシズ, インク. ペプチド基を含む複合体及びそれに関連する方法
JP7664680B2 (ja) 2017-03-29 2025-04-18 リガケム バイオサイエンシズ, インク. ピロロベンゾジアゼピン二量体前駆体及びそのリガンド-リンカーコンジュゲート化合物
US11827703B2 (en) 2018-05-09 2023-11-28 Legochem Biosciences, Inc. Compositions and methods related to anti-CD19 antibody drug conjugates
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
WO2022268644A1 (en) * 2021-06-21 2022-12-29 Syddansk Universitet Inhibitors for use in prevention- and/or alleviation of heart fibrosis
CA3248038A1 (en) 2022-04-12 2023-10-19 Minerva Biotechnologies Corporation ANTI-MUC1* VARIABLE ANTIBODIES AND RELATED USES

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
WO1988006630A1 (en) 1987-03-02 1988-09-07 Genex Corporation Method for the preparation of binding molecules
WO1988007085A1 (en) 1987-03-20 1988-09-22 Creative Biomolecules, Inc. Process for the purification of recombinant polypeptides
AU601273B2 (en) 1987-03-20 1990-09-06 Creative Biomolecules, Inc. Leader sequences for the production of recombinant proteins
JPH02500329A (ja) 1987-05-21 1990-02-08 クリエイテイブ・バイオマリキユールズ・インコーポレーテツド ターゲット化多機能蛋白質
WO2008056833A1 (en) * 2006-11-10 2008-05-15 Livtech Inc. ANTI-HUMAN Dlk-1 ANTIBODY SHOWING ANTI-TUMOR ACTIVITY IN VIVO
WO2009116670A1 (ja) * 2008-03-17 2009-09-24 株式会社リブテック in vivoで抗腫瘍活性を有する抗ヒトDlk-1抗体
KR101461706B1 (ko) * 2011-04-04 2014-11-18 한국생명공학연구원 Dlk1 세포 외 수용성 도메인을 포함하는 액티빈 수용체 타입 2b 억제제
WO2012138102A2 (ko) * 2011-04-04 2012-10-11 한국생명공학연구원 Dlk1 특이적 인간 항체 및 이를 포함하는 약학적 조성물
DK2707031T3 (da) 2011-05-08 2019-10-07 Legochem Biosciences Inc Protein-active agent conjugates and method for preparing the same
KR101628872B1 (ko) * 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
CN107847605B (zh) * 2015-11-25 2021-12-24 乐高化学生物科学股份有限公司 包含分支接头的抗体-药物缀合物及其相关方法
GB201617466D0 (en) * 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
WO2018146199A1 (en) * 2017-02-08 2018-08-16 Adc Therapeutics Sa Pyrrolobenzodiazepine-antibody conjugates
KR101966672B1 (ko) 2017-03-22 2019-04-09 신화인터텍 주식회사 파장 변환 부재 및 이를 포함하는 디스플레이 장치
JP7664680B2 (ja) 2017-03-29 2025-04-18 リガケム バイオサイエンシズ, インク. ピロロベンゾジアゼピン二量体前駆体及びそのリガンド-リンカーコンジュゲート化合物
WO2018182341A1 (ko) * 2017-03-29 2018-10-04 주식회사 레고켐 바이오사이언스 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
KR102286050B1 (ko) 2017-06-23 2021-08-03 현대자동차주식회사 차량 네트워크에서 진단 오류 방지를 위한 방법 및 장치
KR20190018400A (ko) * 2017-08-14 2019-02-22 주식회사 레고켐 바이오사이언스 EGFRvIII에 대한 항체를 포함하는 항체 약물 접합체
WO2019050362A2 (ko) * 2017-09-08 2019-03-14 주식회사 와이바이오로직스 인간 dlk1에 대한 항체 및 이의 용도
KR20200084802A (ko) * 2019-01-03 2020-07-13 주식회사 레고켐 바이오사이언스 안전성이 향상된 피롤로벤조디아제핀 이량체 화합물 및 이의 용도

Similar Documents

Publication Publication Date Title
JP2021523232A5 (cg-RX-API-DMAC7.html)
JP2021063058A5 (cg-RX-API-DMAC7.html)
JP2023531252A5 (cg-RX-API-DMAC7.html)
EP4321180A1 (en) Antibody-drug conjugate including antibody against human cldn18.2, and use thereof
JP2019503980A5 (cg-RX-API-DMAC7.html)
AU2016279051B2 (en) Delivery systems for controlled drug release
HRP20240795T1 (hr) Konjugati koji se sastoje od samozapaljujućih skupina i postupci povezani s njima
JP2019503979A5 (cg-RX-API-DMAC7.html)
JP2019503981A5 (cg-RX-API-DMAC7.html)
CN120076831A (zh) 抗ror1抗体和抗体缀合物、包含抗ror1抗体或抗体缀合物的组合物、以及制备和使用抗ror1抗体和抗体缀合物的方法
KR102187410B1 (ko) 치료제를 전달하기 위한 pH-민감성 링커
TW201729844A (zh) 關於抗-cd19抗體藥物共軛物之組合物及方法
TW201722480A (zh) 關於抗-egfr抗體藥物共軛物之組合物及方法
EP3936150A1 (en) Antibody-drug conjugates including antibody against human dlk1, and use thereof
KR20160068738A (ko) 운시알라마이신의 유도체, 합성 방법 및 항종양 제제로서 이들의 용도
AU2020233532B2 (en) Antibody-drug conjugates including antibody against human DLK1, and use thereof
CN116036303B (zh) 一种抗体-药物偶联物及其制备方法和应用
JP2022530482A (ja) トリス構造を有するリンカーを含むリガンド―薬物複合体
JP2026510495A (ja) ヒトl1camに対する抗体を含む抗体-薬物コンジュゲートおよびその使用
JP7038663B2 (ja) 環中に少なくとも2個の(-ch2-ch2-0-)単位を含むリンカーを含むコンジュゲート及びコンジュゲート試薬
JP2025511705A5 (cg-RX-API-DMAC7.html)
EP3770170A1 (en) Screening of fixed-point coupling sites of cysteine-modified antibody-toxin conjugate (tdc)
RU2021128538A (ru) Коньюгаты антитело-лекарственное средство, включающие антитело против человеческого dlk1, и их применение
KR102501394B1 (ko) 트리스 구조를 가지는 링커를 포함하는 리간드-약물 접합체
RU2020140202A (ru) Композиции и способы, относящиеся к конъюгатам лекарственных средств с антителами против cd19